TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06978647: An Exploratory Clinical Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Diseases

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,090,820

Rescue Site Savings

+$3,354,780

Unlock Full NCT06978647 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06978647 Rescue Dossier →